• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期丙戊酸治疗不会减小潜伏性HIV储存库的规模。

Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.

作者信息

Sagot-Lerolle Nathalie, Lamine Aurelia, Chaix Marie-Laure, Boufassa Faroudy, Aboulker Jean-Paul, Costagliola Dominique, Goujard Cécile, Pallier Coralie, Delfraissy Jean-François, Lambotte Olivier

机构信息

INSERM, U802, Bicêtre, France.

出版信息

AIDS. 2008 Jun 19;22(10):1125-9. doi: 10.1097/QAD.0b013e3282fd6ddc.

DOI:10.1097/QAD.0b013e3282fd6ddc
PMID:18525257
Abstract

OBJECTIVE

To investigate the impact of prolonged valproic acid treatment on the HIV reservoir in patients on highly active antiretroviral therapy.

DESIGN

In a single-center pilot study, the size of the HIV reservoir of 11 patients receiving valproic acid for seizures for more than 2 years was compared with 13 matched patients. In addition, the outcome of patients receiving valproic acid in the French clinical trials of scheduled treatment interruption was recorded.

METHODS

Total and integrated HIV-1 DNA in, respectively, peripheral blood mononuclear cells and CD4 T cells of the patients were quantified by real-time PCR methods. The frequency of CD4 T cells carrying replication-competent virus was estimated by a quantitative limiting-dilution assay in which virus growth was detected by RT-PCR in culture supernatants of activated CD4 T cells. Clinical charts of the patients included in scheduled treatment interruption trials receiving valproic acid were reviewed.

RESULTS

Total and integrated HIV DNA were logarithmically more abundant than cells carrying replication-competent virus, but there was no significant difference in these three parameters between the two groups of matched patients. Three patients receiving valproic acid were included in scheduled treatment interruption trials. The rebound of viral replication was similar to that of the other patients of the trials.

CONCLUSION

Long-term valproic acid therapy seems to be insufficient to reduce the size of the HIV-1 reservoir.

摘要

目的

探讨长期丙戊酸治疗对接受高效抗逆转录病毒治疗患者体内HIV储存库的影响。

设计

在一项单中心试点研究中,将11例因癫痫接受丙戊酸治疗超过2年的患者的HIV储存库大小与13例匹配患者进行比较。此外,记录了法国定期治疗中断临床试验中接受丙戊酸治疗患者的结果。

方法

通过实时PCR方法分别对患者外周血单核细胞和CD4 T细胞中的总HIV-1 DNA和整合HIV-1 DNA进行定量。通过定量极限稀释试验估计携带具有复制能力病毒的CD4 T细胞的频率,在该试验中,通过RT-PCR在活化的CD4 T细胞培养上清液中检测病毒生长。对接受丙戊酸治疗的定期治疗中断试验中患者的临床图表进行了回顾。

结果

总HIV DNA和整合HIV DNA在对数上比携带具有复制能力病毒的细胞丰富,但两组匹配患者在这三个参数上没有显著差异。3例接受丙戊酸治疗的患者被纳入定期治疗中断试验。病毒复制的反弹与试验中的其他患者相似。

结论

长期丙戊酸治疗似乎不足以减小HIV-1储存库的大小。

相似文献

1
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir.长期丙戊酸治疗不会减小潜伏性HIV储存库的规模。
AIDS. 2008 Jun 19;22(10):1125-9. doi: 10.1097/QAD.0b013e3282fd6ddc.
2
Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.丙戊酸联合高效抗逆转录病毒疗法降低系统性 HIV-1 储存库:来自一项多中心随机临床研究的结果。
HIV Med. 2012 May;13(5):291-6. doi: 10.1111/j.1468-1293.2011.00975.x. Epub 2012 Jan 26.
3
Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART.高效抗逆转录病毒治疗(HAART)长期治疗后外周血CD4淋巴细胞和单核细胞中总HIV-1 DNA与整合HIV-1 DNA的比较分析
J Infect. 2001 Nov;43(4):239-45. doi: 10.1053/jinf.2001.0875.
4
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.单次治疗中断后HIV-1病毒反弹动力学取决于高效抗逆转录病毒疗法开始的时间。
AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.
5
Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.常规临床样本中全细胞相关及整合型人类免疫缺陷病毒1型(HIV-1)DNA形式的坐标测量方法的开发:其水平与临床参数无关,但低水平的整合型HIV-1 DNA可能对持续成功治疗具有预后意义。
J Clin Microbiol. 2007 Apr;45(4):1288-97. doi: 10.1128/JCM.01926-06. Epub 2007 Feb 21.
6
New research finds possible treatment for latent HIV. Valproic acid used to deplete HIV.新研究发现了针对潜伏性艾滋病毒的可能治疗方法。丙戊酸用于消耗艾滋病毒。
AIDS Alert. 2005 Dec;20(12):136-8.
7
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.接受高效抗逆转录病毒治疗(HAART)的HIV感染患者外周血单个核细胞中HIV复制与胆固醇之间的关联。
J Antimicrob Chemother. 2008 Feb;61(2):400-4. doi: 10.1093/jac/dkm470. Epub 2007 Dec 14.
8
Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment.长期CD4+细胞计数指导下抗逆转录病毒治疗中断的预后因素
J Med Virol. 2009 Mar;81(3):481-7. doi: 10.1002/jmv.21424.
9
Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.暴露于核苷类逆转录酶抑制剂的HIV感染患者及未接受抗逆转录病毒治疗的患者中,T淋巴细胞和B淋巴细胞线粒体DNA丢失的不同机制。
J Infect Dis. 2008 Nov 15;198(10):1474-81. doi: 10.1086/592713.
10
HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.艾滋病毒/艾滋病。针对潜伏性艾滋病毒的新型治疗方法报告引发了“治愈”一词的讨论。
Science. 2005 Aug 12;309(5737):999-1000. doi: 10.1126/science.309.5737.999a.

引用本文的文献

1
Seizures in brain tumors: pathogenesis, risk factors and management (Review).脑肿瘤中的癫痫发作:发病机制、危险因素与管理(综述)
Int J Mol Med. 2025 May;55(5). doi: 10.3892/ijmm.2025.5523. Epub 2025 Mar 21.
2
Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir.Tat RNA 纳米颗粒可有效逆转潜伏,实现 HIV-1 储存库的多组学分析。
Nat Commun. 2023 Dec 18;14(1):8397. doi: 10.1038/s41467-023-44020-5.
3
New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention.
治疗性操纵 HIV-1 转录和潜伏期的新概念:潜伏期逆转与潜伏期预防。
Viruses. 2023 Jul 31;15(8):1677. doi: 10.3390/v15081677.
4
HIV-1 latency reversal agent boosting is not limited by opioid use.HIV-1潜伏逆转剂增强不受阿片类药物使用的限制。
medRxiv. 2024 Jun 4:2023.05.26.23290576. doi: 10.1101/2023.05.26.23290576.
5
The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.BAF 复合物抑制剂乙胺嘧啶逆转了接受抗逆转录病毒治疗的 HIV-1 感染者中的 HIV-1 潜伏期。
Sci Adv. 2023 Mar 17;9(11):eade6675. doi: 10.1126/sciadv.ade6675. Epub 2023 Mar 15.
6
Design, synthesis, and biological evaluation of AV6 derivatives as novel dual reactivators of latent HIV-1.作为新型潜伏性HIV-1双重激活剂的AV6衍生物的设计、合成及生物学评价
RSC Adv. 2018 May 11;8(31):17279-17292. doi: 10.1039/c8ra01216d. eCollection 2018 May 9.
7
β-catenin regulates HIV latency and modulates HIV reactivation.β-连环蛋白调节 HIV 潜伏期并调节 HIV 再激活。
PLoS Pathog. 2022 Mar 7;18(3):e1010354. doi: 10.1371/journal.ppat.1010354. eCollection 2022 Mar.
8
Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.Bryostatin-1 可降低人原代巨噬细胞中的 HIV-1 感染和病毒产生。
J Virol. 2022 Feb 23;96(4):e0195321. doi: 10.1128/JVI.01953-21. Epub 2021 Dec 8.
9
Challenges and Promise of Human Immunodeficiency Virus Remission.人类免疫缺陷病毒缓解的挑战与前景。
J Infect Dis. 2021 Feb 15;223(12 Suppl 2):4-12. doi: 10.1093/infdis/jiaa568.
10
Epigenetic Compound Screening Uncovers Small Molecules for Reactivation of Latent HIV-1.表观遗传化合物筛选揭示了潜伏 HIV-1 重新激活的小分子。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01815-20.